Tasmanian Devils Face Threats from Rapidly Evolving Facial Cancers

A genetic study tracked the evolution of two transmissible cancers currently ravaging populations of Tasmanian devils.

Written byNatalia Mesa, PhD
| 3 min read
Max Stammnitz
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Tasmanian devil populations have dwindled in recent decades due to two contagious facial cancers that cause debilitating growths. Now, alongside an international group of scientists and organizations, researchers from University of Cambridge conducted a large genetic sequencing study published in Science, and found that one of those cancers is evolving at an alarming pace and may pose a grave threat to Tasmania’s top carnivore.1

This study is the first to track the evolution of the two cancers, creating a detailed account of when the cancers arose, how they spread across the landscape, and importantly, which mutations helped them spread over time.

See also: Tasmanian Devil Cancer Immunotherapy

Carolyn Hogg, a biologist at the University of Sydney who was not involved in the study, said that the research team has generated useful tools to study the devils. “You can make massive headway into understanding how the species [and] disease move through the landscape, and how the disease mutates and changes,” with genomic data, she said.

Devilish diseases

Tasmanian devils are the world’s largest carnivorous marsupials, native to only Tasmania, an island off the coast of southeast Australia. For more than 30 years, these marsupials have been battling two deadly facial cancers, devil facial tumor 1 (DFT1) and devil facial tumor 2 (DFT2). A unique feature of these cancers is that they primarily spread through biting, a common occurrence in devils during fights over mates and food. Transmissible tumors are exceedingly rare in nature, making the devils important models for studying cancer evolution.

See also: Tasmanian Devil Antibodies Fight Cancer

Since its discovery in 1996, DFT1 has “spread throughout Tasmania and almost throughout the entire devil population,” said study coauthor Elizabeth Murchison, a cancer geneticist at the University of Cambridge. The devil population has consequently dropped by 60%, although recent research has shown that devils may be developing resistance toward the disease.2 DFT2 was discovered in 2014 and has only spread to a small corner of southeast Tasmania, but little is known about this second cancer.

Continue reading below...

Like this story? Sign up for FREE Cancer updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Having studied the devils for decades, Murchison “wanted to compare the evolution of the two cancers by looking in detail at the mutations that have occurred in populations of these tumors.” Crucially, she wanted to understand the common features and mutations in these transmissible cancers that aid their spread.

Twin threats

Murchison previously put together a Tasmanian devil reference genome, but gaps remained. Advancements in sequencing technology allowed her team to create an updated version of the reference genome for this study to better understand conserved genes between individuals. The team also sequenced cells from 78 DFT1 and 41 DFT2 Tasmanian devil tumors. Then by comparing the tumors with the reference genome, the team constructed a phylogenetic tree of the two cancers. This allowed them pinpoint when the cancers first arose, when mutations came about, and what mutations the two diseases shared.

“The first surprise was that DFT2 acquires mutations about three times faster than DFT1,” said Murchison.

Tasmanian devil with facial tumor
Tasmanian devil populations are dwindling as they battle two contagious facial cancers that spread via biting when the animals fight or mate.
Max Stammnitz

That’s probably bad very news for the devils, she added, because DFT2 may be more likely to acquire mutations that enhance its spread. However, DFT2 hasn’t spread much yet. More work needs to be done to understand the magnitude of this threat, according to Hogg.

The sequencing results suggest that DFT1 emerged in 1986, 10 years earlier than it was first detected in a female devil in northeast Tasmania. The analysis also provided clues about how the disease spread throughout the island, revealing that early on, a female super spreader infected roughly six others, resulting in at least six major variants of DFT1.

DFT2 emerged in 2011, three years before researchers spotted a male devil with infectious cancer in the southeast corner of the island.

Some of the same mutations popped up repeatedly, indicating that selective pressures may drive their spread. In several instances, they found that DFT2, which originated from a male devil, had developed a mutation that eliminated its Y chromosome, perhaps to spread to female devils more easily. The researchers also found evidence in both cancers for two dimer-forming, cell surface-dwelling tyrosine kinase proteins called platelet-derived growth factor a (PDGFA) and platelet-derived growth factor b (PDGFB), which are involved in cell growth and also implicated in cancer in other species, including humans.

DFT1 and DFT2 are long-lived and can be repeatedly sampled over time, according to Murchison. She hopes that the findings will help conserve Tasmanian devils. “We can get certain insights into the temporal evolution of cancer,” she said. “This helps us understand what might happen in the future.”

  1. Stammnitz MR , et al. The evolution of two transmissible cancers in Tasmanian devils. Science. 2023;380(6642):283-293.
  2. Epstein B, et al. Rapid evolutionary response to a transmissible cancer in Tasmanian devils.Nat. Commun. 2016;7(1).

Related Topics

Meet the Author

  • A black and white headshot

    As she was completing her graduate thesis on the neuroscience of vision, Natalia found that she loved to talk to other people about how science impacts them. This passion led Natalia to take up writing and science communication, and she has contributed to outlets including Scientific American and the Broad Institute. Natalia completed her PhD in neuroscience at the University of Washington and graduated from Cornell University with a bachelor’s degree in biological sciences. She was previously an intern at The Scientist, and currently freelances from her home in Seattle. 

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform